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a  b  s  t  r  a  c  t
In the  studies  presented  here,  dogs  were  vaccinated  against  Leishmania  (Leishmania)  cha-
gasi challenge  infection  using  a preparation  of  Leishmania  braziliensis  promastigote  proteins
and  saponin  as  adjuvant  (LBSap).  Vaccination  with  LBSap  induced  a prominent  type  1
immune  response  that  was  characterized  by  increased  levels  of  interleukin  (IL-)  12 and
interferon  gamma  (IFN-)  production  by  peripheral  blood  mononuclear  cells  (PBMC)  upon
stimulation  with  soluble  vaccine  antigen.  Importantly,  results  showed  that  this  type  of
responsiveness  was  sustained  after  challenge  infection;  at day  90  and  885 after L. chagasi
challenge  infection,  PBMCs  from  LBSap  vaccinated  dogs  produced  more  IL-12,  IFN-  and
concomitant  nitric  oxide  (NO)  when  stimulated  with  Leishmania  antigens  as  compared
to  PBMCs  from  respective  control  groups  (saponin,  LB- treated,  or  non-treated  control
dogs).  Moreover,  transforming  growth  factor  (TGF)-  decreased  in the  supernatant  of  SLcA-
stimulated  PBMCs  in the LBSap  group  at 90 days.  Bone  marrow  parasitological  analysis
revealed  decreased  frequency  of parasitism  in  the  presence  of  vaccine  antigen.  It  is con-
cluded  that  vaccination  o
response  against  L.  chagas
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1. Introduction
Visceral leishmaniasis with a zoonotic feature is caused
by protozoan species belonging to the complex Leishmania
donovani (Leishmania infantum syn. Leishmania chagasi, in
Latin America) and is widely distributed in the Mediter-
ranean Basin, Middle East, and South America (Desjeux,
2004). Canines are the main reservoir for the parasite in dif-
ferent geographical regions of the globe and play a relevant
role in transmission to humans (Deane, 1961; Dantas-
Torres, 2006). Thus, the current strategy for control of the
disease includes the detection and elimination of seropos-
itive dogs alongside vector control and therapy for human
infection (Tesh, 1995). Chemotherapy in dogs still does not
provide parasitological cure (Noli and Auxilia, 2005), and
for this reason a vaccine against visceral leishmaniasis (VL)
would be an important tool in the control of canine visceral
leishmaniasis (CVL) and would also dramatically decrease
the infection pressure of L. chagasi for humans (Hommel
et al., 1995; Dye, 1996).
Toward this purpose, establishing biomarkers of
immunogenicity is considered critical in analyzing can-
didate vaccines against CVL (Reis et al., 2010; Maia and
Campino, 2012), and this strategy is being used to iden-
tify the pattern of immune response in dogs and to further
the search for vaccine candidates against CVL (Reis et al.,
2010). Several studies have reported the potential of differ-
ent CVL vaccines to trigger immunoprotective mechanisms
against Leishmania infection (Borja-Cabrera et al., 2002;
Rafati et al., 2005; Holzmuller et al., 2005; Giunchetti
et al., 2007; Lemesre et al., 2007; Araújo et al., 2008, 2009;
Fernandes et al., 2008; Giunchetti et al., 2008a,b).
The polarized immune response described in a mouse
model during Leishmania infection (Mosman et al., 1986;
Barral et al., 1993; Kane and Mosser, 2001; Murray et al.,
2002; Trinchieri, 2007) does not occur in dogs, with dif-
ferent studies demonstrating the simultaneous presence
of interferon (IFN)-  and interleukin (IL)-10 (Chamizo
et al., 2005; Lage et al., 2007; Menezes-Souza et al.,
2011). In addition, a mixed proﬁle of cytokines has been
described during CVL, with high levels of IFN-, IL-10,
and transforming growth factor (TGF)-,  concomitant with
reduced expression of IL-12 according to skin parasite load
(Menezes-Souza et al., 2011).
Studies evaluating other biomarkers of immunogenicity
induced by the LBSap vaccine (composed of L. brazilien-
sis promastigote proteins plus saponin as the adjuvant)
have demonstrated higher levels of circulating T lympho-
cytes (CD5+, CD4+, and CD8+) and B lymphocytes (CD21+)
and increased levels of Leishmania-speciﬁc CD8+ and CD4+
T cells (Giunchetti et al., 2007, 2008a). LBSap vaccine is
considered safe for administration, without induction of
ulcerative lesions at the site of inoculation (Giunchetti
et al., 2007; Vitoriano-Souza et al., 2008). Moreover, LBSap
vaccinated dogs presented high IFN- and low IL-10 and
TGF-1 expression in the spleen, with signiﬁcant reduction
of parasite load in this organ (Roatt et al., 2012). Addition-
ally, LBSap displayed a strong and sustained induction of
humoral immune response, with increased levels of anti-
Leishmania total IgG as well as both IgG1 and IgG2, after
experimental challenge (Roatt et al., 2012).itology 198 (2013) 371– 381
Considering the promising results of the LBSap vac-
cine, we  aimed to further evaluate the immunogenicity
biomarkers before and after experimental L. chagasi chal-
lenge. Thus, the proﬁle of different cytokines (IL-4, IL-10,
TGF-, IL-12, IFN-, and tumor necrosis factor [TNF]-)
and nitric oxide (NO) in supernatants of peripheral blood
mononuclear cell (PBMC) cultures were evaluated before
the ﬁrst immunization (T0), 15 days after completion of
the vaccine protocol (T3), and at time points 90 (T90) and
885 (T885) days after experimental L. chagasi challenge. The
frequency of parasitism in the bone marrow was  also eval-
uated until T885.
2. Materials and methods
2.1. Animals, vaccination and experimental challenge
with L. chagasi plus saliva of Lutzomyia longipalpis
Twenty male and female mongrel dogs that had been
born and reared in the kennels of the Instituto de Ciên-
cias Exatas e Biológicas, Universidade Federal de Ouro
Preto, Ouro Preto, Minas Gerais, Brazil, were treated at
7 months with an anthelmintic and vaccinated against
rabies (Tecpar, Curitiba-PR, Brazil), canine distemper,
type 2 adenovirus, coronavirus, parainﬂuenza, parvovirus,
and leptospira (Vanguard® HTLP 5/CV-L; Pﬁzer Animal
Health, New York, NY, USA). The absence of speciﬁc
anti-Leishmania antibodies was  conﬁrmed by indirect ﬂu-
orescence immunoassay. Experimental dogs were divided
into four experimental groups: (i) control (C) group (n = 5)
received 1 ml  of sterile 0.9% saline; (ii) LB group (n = 5)
received 600 g of L. braziliensis promastigote protein in
1 ml  of sterile 0.9% saline; (iii) Sap group (n = 5) received
1 mg  of saponin (Sigma Chemical Co., St. Louis, MO,  USA)
in 1 ml  of sterile 0.9% saline; and (iv) LBSap group (n = 5)
received 600 g of L. braziliensis promastigote protein and
1 mg  of saponin in 1 ml  of sterile 0.9% saline. All animals
received subcutaneous injections in the right ﬂank at inter-
vals of 4 weeks for a total of three injections. The challenge
of experimental animals was performed after 100 days of
vaccination protocol. In this sense, all dogs received intra-
dermally 1.0 × 107 promastigotes of L. chagasi stationary
phase of cultivation, in the inner side of the left ear, in addi-
tion to 5 acini of the salivary gland of L. longipalpis. This
preliminary stage of the study was  performed from 2005
to 2007.
2.2. Vaccine preparation
Promastigotes of L. braziliensis (MHOM/BR/75/M2903)
were maintained in in vitro culture in NNN/LIT media as
previously described (Giunchetti et al., 2007). Brieﬂy, para-
sites were harvested by centrifugation (2000 × g, 20 min,
4 ◦C) from 10-day-old cultures, washed three times in
saline buffer, fully disrupted by ultrasound treatment
(40 W,  1 min, 0 ◦C), separated into aliquots, and stored at
−80 ◦C until required for use. Protein concentration was
determined according to the method of Lowry (Lowry
et al., 1951). The LBSap vaccine was  previously described
by Giunchetti et al., 2007 and registered at the Instituto
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acional da Propriedade Industrial (Brazil) under patent
umber PI 0601225-6 (17 February 2006).
.3. Blood sample collection and in vitro assays
Peripheral blood samples were collected before the
rst immunization (T0), 15 days after completion of the
accine protocol (T3) and at time points of 90 (T90) and
85 (T885) days after experimental L. chagasi challenge by
uncture of the jugular vein in sterile heparinized 20 ml
yringes. To obtain PBMCs for the in vitro analysis, the
lood collected was added over 10 ml  of Ficoll-Hypaque
Histopaque® 1077, Sigma) and subjected to centrifugation
t 450 × g for 40 min  at room temperature. The separated
BMCs were resuspended in Gibco RPMI1640 medium,
ashed twice with RPMI 1640, centrifuged at 450 × g for
0 min  at room temperature, homogenized, and ﬁnally
esuspended in RPMI 1640 at 107 cells/ml as previously
escribed (Giunchetti et al., 2007).
The in vitro assays were performed in 48-well ﬂat-
ottomed tissue culture plates (Costar, Cambridge, MA,
SA), with each well containing 650 l of culture medium
10% fetal bovine serum/1% streptavidin/penicillin, 2 mM l-
lutamine, and 0.1% -mercaptoethanol in RPMI 1640) and
0 l of PBMCs (5.0 × 105 cells/well) with 100 l of vaccine
oluble antigen (VSA; L. braziliensis, 25 g/ml) or 100 l of
oluble L. chagasi antigen (SLcA, 25 g/ml) obtained accord-
ng to Reis et al. (Reis et al., 2006a,b). One-hundred l
f RPMI was added in place of the antigenic stimulus in
he non-stimulated control cultures. Incubation was  car-
ied out in a humidiﬁed incubator with 5% CO2, at 37 ◦C for
 days, after which the supernatants were collected and
tored in a freezer at −80 ◦C for detection of cytokine and
O.
The in vitro evaluation was performed with the super-
atant of PBMCs collected at T0, T3, T90 and T885, which
ere stored as described above.
.4. Quantiﬁcation of cytokines
Cytokine levels were determined by enzyme-linked
mmunosorbent assay (ELISA), purchased from R&D
ystems (Minneapolis, MN,  USA), according to the manu-
acturer’s instructions. DuoSet ELISA was used for analysis
f TNF- (anti-canine TNF-/TNFSF1A immunoassay; cat-
log number: DY1507); IL-10 (anti-canine IL-10, catalog
umber: DY735); IL-12 (anti-canine IL-12/IL-23 p40, cat-
log number: DY1969); and IFN- (anti-canine IFN-,
atalog number: DY781B) cytokines. The level of TGF-
 was quantiﬁed by ELISA using the Quantikine® kit
mouse/rat/porcine/canine TGF-1 immunoassay, cata-
og number MB100B). IL-4 cytokine was evaluated using
onoclonal anti-canine IL-4 antibody (catalog number:
AB7541) as capture antibody; recombinant canine IL-4
catalog number: 754CL) for obtaining the standard curve;
nd biotinylated anti-canine IL-4 antibody (catalog num-
er: BAF754), streptavidin (R&D Systems, DY998), and
ubstrate solution (1:1 mixture of H2O2 and tetramethyl-
enzidine, product code 50-76-4, lot. no. RB49). Minimum
ensitivity was 63 pg/ml for TNF-, 78 pg/ml for IL-10,itology 198 (2013) 371– 381 373
62 pg/ml for IL-12, 63 pg/ml for IFN-, 31 pg/ml for TGF-,
and 78 pg/ml for IL-4.
All experiments were performed using 96-well plates
(COSTAR®, Washington, DC), according to R&D Sys-
tems instructions. The reading was  performed using the
microplate automatic reader (EL800, Biotek, Winosski, VT)
at a wavelength of 450 nm.
2.5. NO production
Quantiﬁcation of levels of NO was performed indirectly
by measuring nitrite in supernatants of PBMC cultures by
Griess reaction (Green et al., 1982; Gutman and Hollywood,
1992). Duplicate samples were grown in 96-ﬂat bottom
wells (Nunc, Naperville, IL). Brieﬂy, a 100-l aliquot of
cell-free culture supernatant was  mixed with 100 l of
Griess reagent (1% sulfanylamide, 0.1% naphthylethylene-
diamide-dihydrochloride, and 2.5% phosphoric acid, all
from Sigma). Following 10 min  of incubation at room tem-
perature in the dark, the absorbance was measured at
540 nm by using a microplate reader (Biotek, EL800). The
concentration of nitrite was determined by interpolation
from a standard curve constructed by using sodium nitrite
solutions of known concentration in the range 0–100 M.
To discount the interference of nitrites already present
in the culture medium, data were calculated taking into
account the blank for each experiment, assayed by using
the medium employed for the in vitro PBMC cultures. The
results were ﬁrst expressed as nitrite concentration (M).
2.6. Parasitological analyze on bone marrow samples
Bone marrow was  obtained to evaluate the frequency of
tissue parasitism in the different groups. Dogs were anes-
thetized with an intravenous dose (8 mg/kg body weight) of
sodium thiopental (Thionembutal®; Abbott Laboratories,
São Paulo, Brazil), and bone marrow ﬂuid was removed
from the iliac crest under aseptic conditions. The bone mar-
row aspirates were used to study the presence of L. chagasi
parasites by PCR.
DNA of bone marrow samples was  extracted by
WizardTM Genomic DNA Puriﬁcation Kit (Promega,
Madison, WI,  USA) according to the manufacturer’s
instructions. PCR was performed as previously described
(Degrave et al., 1994) using the primers 150 forward: [5′-
GGG(G/T)AGGGGCGTTCT(G/C)CGAA-3′] and 152 reverse:
[5′-(G/C)(G/C)(G/C)(A/T)CTAT(A/T)TTACACCAACCCC-3′]
that ampliﬁed a DNA fragment of 120 base pairs (bp)
from the conserved region of Leishmania minicircle kDNA.
Brieﬂy, the PCR assay reaction mixture contained 1.0 l of
DNA preparation, 0.2 mM  dNTPs, 10 mM Tris-HCl (pH 8.0),
50 mM KCl, 1.5 mM MgCl2, 10 pmol of each primer, and 1 U
Taq polymerase (Invitrogen) to a ﬁnal volume of 10 l. PCR
ampliﬁcation was performed in a Veriti Thermal Cycler 96-
well thermocycler (Applied Biosystems®, Irvine, CA, USA),
over 40 cycles consisting of 1 min  at 94 ◦C (denaturation),
1 min  at 64 ◦C (annealing), 1 min  at 72 ◦C (extension),
and 7 min  at 72 ◦C (ﬁnal extension). Positive [genomic
DNA of L. chagasi (MHOM/BR/1972/BH46)] and negative
(without DNA) controls were included in each test. Ampli-
ﬁed fragments were analyzed by electrophoresis on 8%
374 L.A. Resende et al. / Veterinary Paras
Table  1
Levels of TGF- in the PBMCs from dogs before the ﬁrst vaccine dose (T0),
following completion of the vaccine protocol (T3), and after early (T90) and
late (T885) time points following L. chagasi challenge. The results are pre-
sented with regards to stimulation with soluble L. chagasi antigen (SLcA)
in  the following groups: C (control) and LBSap (killed L. braziliensis vaccine
plus saponin).
Time Groups TGF- (CC) TGF- (SLcA)
T0 C 1815 ± 728.5 2229 ± 374.4
LBSap 1735 ± 447.0 2027 ± 680.1
T3 C 3355 ± 817.2 2997 ± 588.8
LBSap 2642 ± 100.1 2553 ± 922.2
T90 C 2928 ± 972.7 3445 ± 170.7
LBSap 1688 ± 803.2 *2278 ± 437.7
T885 C 1704 ± 457.7 1857 ± 333.8
LBSap 1437 ± 259.5 1427 ± 296.2* Signiﬁcant difference (P < 0.05) between the C and LBSap groups by
different times of evaluation.
polyacrylamide gel and ethidium bromide-stained for the
PCR product identiﬁcation.
The parasitological investigation was performed until
885 days after L. chagasi challenge.
2.7. Statistical analysis
Statistical analyses were performed using Prism 5.0
software package (Prism Software, Irvine, CA, USA). Nor-
mality of the data was demonstrated using a Kolmogorov-
Smirnoff test. Paired t-tests were used to evaluate
differences in mean values of cytokines levels, consider-
ing the comparative analysis of T0 and T3 (Fig. 1) or T90
(Fig. 2) or T885 (Fig. 3), in each group evaluated. Unpaired t-
tests were used to evaluate differences in mean of values of
TGF- (Table 1). Analysis of variance (ANOVA) test followed
by Tukey’s multiple comparisons were used in the evalua-
tion between the different treatment groups for cytokines
(Figs. 1–3) and nitric oxide (Fig. 4) analysis. Differences
were considered signiﬁcant when P values were <0.05.
3. Results
3.1. LBSap induced a prominent type 1 immune response
elicited by higher levels of IL-12 and IFN- post vaccine
protocol
To determine the impact of LBSap vaccination on the
immune response, we evaluated the cytokine proﬁle (TNF-
, IL-12, IFN-, IL-4, and IL-10) in the supernatant of PBMC
stimulated with VSA (Fig. 1A) or SLcA (Fig. 1B). In this con-
text, we performed a comparative analysis between T0 and
T3, in addition to the comparisons between experimental
groups at each time point. In the comparison between T0
and T3, the Sap group showed increased levels (P < 0.05)
of TNF- and IFN- production at T3 with VSA stimulation.
Additionally, the LB group presented higher levels (P < 0.05)
of IL-10 in VSA-stimulated PBMCs at T3, as compared to T0.
In contrast, in SLcA-stimulated cultures, the LB group dis-
played lower levels of TNF- at T3 as compared to T0 in
SLcA-stimulated cultures (P < 0.05).itology 198 (2013) 371– 381
Interestingly, the LBSap vaccine induced higher levels
of both IL-12 and IFN- at T3 in VSA-stimulated PBMCs.
Similarly, in the presence of SLcA, increased levels (P < 0.05)
of IFN- were observed in the LBSap group at T3.
The comparison between the experimental groups, in
different time points, revealed increased levels (P < 0.05)
of IFN- in VSA-stimulated cultures from the LB group, as
compared to C group in T3. Interestingly, higher (P < 0.05)
levels of this cytokine were observed in the VSA-stimulated
culture of LBSap group when compared to C and Sap groups,
at T3. Similarly, in SLcA-stimulated cultures, LBSap group
displayed increased (P < 0.05) levels of IFN- in relation to
C, Sap and LB groups at T3. In addition, at T3, LBSap group
showed increased (P < 0.05) levels of IL-12 in relation to C
and Sap groups, in addition to reduced (P < 0.05) levels of IL-
10 when compared to LB group, in VSA-stimulated cultures.
3.2. Both IL-12 and IFN- markedly increased in
response to LBSap vaccine at T90
The early immune response after L. chagasi challenge
was  analyzed in different groups. We  determined the
cytokine patterns in the supernatant of PBMCs comparing
the different treatments (VSA – Fig. 2A and SLcA – Fig. 2B),
different time points (T0 and T90), and different experimen-
tal groups, at each time point.
Comparison between T0 and T90 showed that the C
group had increased levels of TNF- production (P < 0.05)
and lower levels of IL-4 production (P < 0.05) at T90 upon
VSA and SLcA stimulation. Additionally, C group had higher
levels of IL-12 in SLcA-stimulated PBMCs (P < 0.05) and
higher levels of IFN- production in VSA-stimulated PBMCs
(P < 0.05) at T90. The Sap group showed increased levels
(P < 0.05) of TNF- and IL-10 production and reduction
of IL-4 levels at T90. In SLcA-stimulated cultures, the Sap
group presented higher levels (P < 0.05) of TNF- and IFN-
. The LB group showed increased levels (P < 0.05) of TNF-,
IL-12, and IL-10 production and reduction of IL-4 in VSA-
stimulated PBMCs at T90. In cultures stimulated with SLcA,
the LB group shown increased levels (P < 0.05) of IFN-.
Interestingly, the LBSap vaccine induced higher levels of IL-
12 at T90 in PBMCs stimulated with VSA. Furthermore, in
the presence of SLcA, LBSap vaccine induced higher levels of
IFN- (P < 0.05). The reduced levels of IL-4, which occurred
in the other groups, were retained (P < 0.05) in the LBSap
group at T90 for both stimuli (VSA and SLcA).
The comparative analysis between the experimental
groups showed, at T90, increased levels (P < 0.05) of IL-4,
in SLcA-stimulated cultures in the LB group and VSA-
stimulated cultures in the LBSap group, in relation to
C group. Interestingly, the SLcA-stimulated PBMCs from
LBSap group showed increased levels (P < 0.05) of IL-12
compared to LB and Sap groups at T90. Furthermore,
increased levels (P < 0.05) of IFN- in the LBSap when com-
pared to C, Sap and LB groups were observed.
3.3. LBSap vaccine elicited a long-lasting type 1 immune
response at T885, displaying higher levels of IFN-
The late immune response after L. chagasi challenge was
studied in different groups with regard to the cytokine
L.A. Resende et al. / Veterinary Parasitology 198 (2013) 371– 381 375
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Fig. 1. Impact of vaccination in the immune response based on the cytokine levels in the supernatant of PBMCs submitted to vaccine soluble antigen (VSA,
A  panels) or soluble L. chagasi antigen (SLcA, B panels). Data are displayed as a comparative analysis between the time point prior to vaccination (T0) and 15
days  after completion of the vaccine protocol (T3). The groups are represented as C (control; ); Sap (saponin; ); LB (killed L. braziliensis vaccine; ); and
LBSap (killed L. braziliensis vaccine plus saponin; ). The x-axis displays the cytokines evaluated (TNF-, IL-12, IFN-, IL-4, and IL-10). The y-axis represents
the  mean values (pg/ml) ± SD from groups of ﬁve animals/evaluation time; the left y-axes depict the TNF-, IL-4, and IL-10 levels, while in the right y-axes
represent the IL-12 and IFN- cytokine levels. Signiﬁcant differences (P < 0.05) between values measured at T0 (before the ﬁrst dose) and T3 (15 days after
t , Sap, an
r
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(
c
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she  third dose) are indicated by connecting lines, whereas the symbols C
espectively, at the same stimulus and time of evaluation.
evels in the supernatant of PBMCs treated with VSA
Fig. 3A) or SLcA (Fig. 3B), and the T0 and T885 data were
ompared, besides the comparisons between experimental
roups, at each time.
In the comparison between T0 and T885, the results
howed that the C group had increased levels of TNF- ind LB indicate signiﬁcant differences in relation to C, Sap, and LB, groups,
VSA-stimulated PBMCs (P < 0.05) and decreased levels of
IL-4 production (P < 0.05) in the presence of SLcA at T885.
The Sap and LB groups presented increased levels of IL-
12 (P < 0.05) at T885 in the presence of the VSA stimulus,
as compared to T0. In the presence of the SLcA stimu-
lus, the LB group had decreased levels of IL-4 (P < 0.05) at
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Fig. 2. Early immune response after L. chagasi challenge in groups exposed to different vaccines with regard to cytokine levels in the supernatant of PBMCs
treated with vaccine soluble antigen (VSA, A panel) or soluble L. chagasi antigen (SLcA, B panel). Data are displayed as a comparative analysis between the
time  point prior to vaccination (T0) and after the early time point following the L. chagasi challenge (T90). The groups are represented as C (control; ); Sap
(saponin; ); LB (killed L. braziliensis vaccine; ), LBSap (killed L. braziliensis vaccine plus saponin; ). The x-axis depicts the cytokines evaluated (TNF-,
IL-12,  IFN-, IL-4, and IL-10). The y-axis represents the mean values (pg/ml) ± SD from groups of ﬁve animals/evaluation time; the left y-axes illustrate
-12 and
 challen
ctively, the  TNF-, IL-4, and IL-10 levels, while the right y-axes represent the IL
measured at T0 (before the ﬁrst dose) and T90 (90 days after the L. chagasi
indicate  signiﬁcant differences in relation to C, Sap, and LB, groups, respe
T885, as compared to T0. Similarly, the group LBSap had
decreased levels of IL-4 (P < 0.05) at T885, as compared to
T0, but this difference was only observed in the presence
of the VSA stimulus. Interestingly, in this group, levels of
IL-12 (in the presence of VSA) and IFN- (in the presence
of SLcA) were higher compared to T0 (P < 0.05). Whereas
this was a time-delayed response post-challenge with L. IFN- cytokine levels. Signiﬁcant differences (P < 0.05) between values
ge) are indicated by connecting lines, whereas the symbols C, Sap, and LB
at the same stimulus and time of evaluation.
chagasi (T885), this result indicates an immune response
predominantly of the type 1, induced by vaccination with
LBSap.Comparative analysis between the experimental groups
showed increased (P < 0.05) levels of TNF- in VSA-
stimulated cultures of LB group in relation to C group, at
T885. Interestingly, at T885, increased (P < 0.05) levels of
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treated with vaccine soluble antigen (VSA, A panel) or soluble L. chagasi antigen (SLcA, B panel). Data are displayed as a comparative analysis between
the  time point prior to vaccination (T0) and at the late time point following L. chagasi challenge (T885). The groups are represented as C (control; ); Sap
(saponin; ); LB (killed L. braziliensis vaccine; ); and LBSap (killed L. braziliensis vaccine plus saponin; ). The x-axis displays the cytokines evaluated
(TNF-,  IL-12, IFN-, IL-4, and IL-10). The y-axis represents the mean values (pg/ml) ± SD from groups of ﬁve animals/evaluation time; the left y-axes
illustrate the TNF-, IL-4, and IL-10 levels, while in the right y-axes represent the IL-12 and IFN- cytokine levels. Signiﬁcant differences (P < 0.05) between
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IFN- in LBSap group was observed in relation to C, Sap
and LB groups, in SLcA-stimulated PBMCs.
3.4. Impaired levels of TGF-  ˇ were the hallmark of the
LBSap vaccine at T90
The levels of TGF- are shown in Table 1, which focuses
on the analysis using supernatant of PBMCs simulated with
SLcA. We  evaluated the data using a comparative analysis
between the control and LBSap groups at T0 and T3 as well
as at T90 and T885 for the L. chagasi challenge.
Interestingly, there was a decrease in TGF- in the group
immunized with LBSap compared to group C at T90.
3.5. LBSap enhanced NO production at T885 in both VSA-
and SLcA-stimulated cultures
Since the production of NO is considered to be a key
element in mechanisms that mediate the elimination of
intracellular pathogens, the levels of antimicrobial oxidant
produced by in vitro antigen-stimulated PBMCs derived
from dogs vaccinated with LBSap were determined (Fig. 4).
At T90 a reduction (P < 0.05) was observed in the levels
of the reactive NO in VSA-stimulated cultures compared to
the respective control cultures of the groups C, Sap, LB, and
LBSap (Fig. 4A).
At T885, signiﬁcantly increased nitrite levels (P < 0.05) in
the VSA- and SLcA-stimulated cultures were observed in
the Sap group compared with cultures receiving the same
stimuli in the C and LB groups. SLcA-stimulated cultures in
the C and LB groups showed a signiﬁcant reduction of NO
levels when compared to the respective control cultures
(Fig. 4B). In addition, the C group presented higher levels of
NO in control cultures in relation to VSA-stimulated cul-
tures (Fig. 4B). Interestingly, in the LBSap group, higher
(P < 0.05) levels of NO levels were recorded in the super-
natant of SLcA- and VSA-stimulated cultures at T885 when
compared with cultures receiving the same stimuli in
groups C and LB. connecting lines, whereas the symbols C, Sap, and LB indicate signiﬁcant
us and time of evaluation. Data are presented as mean ± SD of NO levels
3.6. Bone marrow parasitological analysis revealed
decreased frequency of parasitism in the presence of
vaccine antigen
The parasitological investigation was performed until
885 days after L. chagasi challenge. By T885 two dogs from
group C, four dogs from group Sap, and one dog each
from the LB and LBSap groups were diagnosed as posi-
tive. It is interesting to note also, that until the period
in which they were accompanied (T885) all experimental
groups remained asymptomatic.
4. Discussion
Increased VL incidence in the world and especially in
Brazil have motivated studies and evaluations of anti-CVL
vaccines because of the epidemiological importance of
dogs in the biological cycle of the parasite (Palatnik-de-
Sousa, 2012). Aiming to guide the rationale for developing
anti-CVL vaccines, studies have been performed to identify
biomarkers of immunogenicity before and after L. chagasi
challenge (Gutman and Hollywood, 1992; Reis et al., 2010).
Type 1 and type 2 immune responses and immunomod-
ulatory cytokines are considered the main targets for
identifying resistance biomarkers following vaccination
against CVL (Reis et al., 2010; Fernandes et al., 2008; Carrillo
et al., 2007; De Lima et al., 2010).
Results from previous studies using LBSap, the anti-
CVL vaccine, showed high immunogenic potential, with
induction of increased levels of circulating T lymphocytes
(CD5+, CD4+, and CD8+) and B lymphocytes (CD21+), and
higher levels of CD4+ and CD8+ T cells that were Leish-
mania speciﬁc (Giunchetti et al., 2007; Roatt et al., 2012).
In these studies, LBSap vaccine elicited strong antigenic-
ity related to the increased levels of anti-Leishmania IgG
isotypes after vaccination (Giunchetti et al., 2007), and
a strong and sustained induction of humoral immune
response after experimental challenge, with increased lev-
els of anti-Leishmania total IgG, IgG1 and IgG2 (Roatt et al.,
2012). Furthermore, LBSap vaccinated dogs presented high
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FN- and low IL-10 and TGF-1 expression in spleen with
igniﬁcant reduction of parasite load in this organ (Roatt
t al., 2012). In addition, LBSap vaccine displayed safety
nd security for the administration (Giunchetti et al., 2007;
itoriano-Souza et al., 2008; Moreira et al., 2009).
However, there are few studies evaluating the cytokine
roﬁles associated with CVL and in anti-CVL vaccines,
hich might serve as biomarkers to identify resistance
nd susceptibility. Thus, this study aimed to evaluate the
ytokine proﬁle and NO induced by immunization before
nd after experimental challenge with L. chagasi and sand
y saliva. In addition, the frequency of bone marrow para-
itism was included in the evaluation.
We  thus performed a comparative analysis of the
ytokine proﬁle before immunization (T0), after comple-
ion of the vaccine protocol (T3), and at early (T90) and
ate (T885) time points after experimental challenge with
. chagasi. The production of distinct cytokines was eval-
ated during the vaccination protocol and after L. chagasi
nd sand ﬂy saliva experimental challenge.
The analysis of IL-4 levels has been considered a mor-
idity marker during ongoing CVL (Quinnel et al., 2001;
rachelente et al., 2005; Chamizo et al., 2005), as well
s in a murine models of VL (Miralles et al., 1994). We
bserved that the group vaccinated with LBSap showed
ncreased levels of IL-4 as compared to the C group. How-
ver, increased levels of IFN- in the LBSap group were
lso observed. According to Manna et al. (2008), it is pos-
ible to maintain a standard of resistance in CVL even in
he presence of IL-4, as long as there are elevated levels
f IFN-. Nevertheless, our results do not suggest a typical
roﬁle linking this cytokine with a resistance or suscepti-
ility pattern in CVL. Similar to our study, a previous study
Manna et al., 2006) did not associate IL-4 with resistance
r susceptibility to natural L. chagasi infection in CVL. In
ontrast, levels of IL-4 in splenocytes from dogs naturally
nfected with L. chagasi and presenting different clinical
igns, indicated that this cytokine could be a biomarker
resent during the course of infection in CVL (Lage et al.,
007).
Similarly, IL-10 has also been associated with suscep-
ibility to CVL (Pinelli et al., 1999; Lage et al., 2007; Alves
t al., 2009; Boggiatto et al., 2010) and human VL (Nylen
nd Sacks, 2007). Our data showed increased levels of IL-
0 at T3 and T90 in the LB group and at T90 in the Sap
roup. In contrast, we observed decreased levels of IL-10
n LBSap in relation to the LB group at T3 in VSA-stimulated
BMCs. We  hypothesize that lower levels of IL-10 during
he immunization protocol and the lack of signiﬁcance in
L-10 levels after experimental challenge with L. chagasi
n the LBSap contributes to the establishment of a more
fﬁcient immune response in these vaccinated dogs.
In addition, the cytokine TGF- has been associated
ith progression of Leishmania infection in a murine model
Barral et al., 1993; Virmondes-Rodrigues et al., 1998; Gantt
t al., 2003). Few studies have been performed in CVL;
owever, existing studies show increased levels of TGF-
 in both asymptomatic and symptomatic dogs naturally
nfected with L. chagasi (Correa et al., 2007). Our results
isplayed decreased levels of TGF- in SLcA-stimulated
ultures of LBSap group at T90. These results suggest thatitology 198 (2013) 371– 381 379
vaccination with LBSap may  trigger reduced TGF- pro-
duction after experimental challenge. In fact, a previous
work (Alves et al., 2009) reported high levels of TGF- asso-
ciated with increased parasite load in lymph nodes from
symptomatic dogs naturally infected with L. chagasi and
an association between this cytokine and CVL morbidity.
Therefore, it is possible that the reduced levels of TGF-
, associated with higher levels of IL-12 and IFN-, after
L. chagasi and sand ﬂy saliva challenge, would contribute
to establishing immunoprotective mechanisms induced by
LBSap vaccination.
Type 1 cytokines have also been considered as a pre-
requisite for evaluating immunogenicity before and after
L. chagasi experimental challenge in anti-CVL vaccine clini-
cal trials (Reis et al., 2010). Thus, we analyzed TNF-, IL-12,
and IFN- levels.
Some studies have established that TNF- together with
IFN- are associated with a resistance proﬁle against CVL
(Pinelli et al., 1994, 1999; Chamizo et al., 2005; Carrillo
et al., 2007; Alves et al., 2009). However, it is not a con-
sensus that TNF- proﬁle would be a good indicator of
resistance or susceptibility after L. chagasi infection, consid-
ering the similar levels of TNF- showed in dogs presenting
distinct clinical signs (De Lima et al., 2007; Lage et al., 2007).
Moreover, LBSap group did not present any differences
in TNF- levels when compared to other experimental
groups. In fact, our data were similar to Leishmune® results,
that did not present differences in the expression of this
molecule (Araújo et al., 2009; De Lima et al., 2010). In addi-
tion, assessment of IL-12 levels in the group immunized
with LBSap revealed increased levels of this cytokine at T3,
T90, and T885 in the presence of VSA stimulation, compared
to T0. Interestingly, higher levels of IL-12 after vaccine pro-
tocol in relation to C and LB group (T3, in VSA-stimulated
cultures), and in the early period post challenge in rela-
tion to Sap and LB groups (T90, in SLcA-stimulated cultures)
was the hallmark of LBSap group. Since this cytokine has
been associated with protection in CVL (Strauss-Ayali et al.,
2005; Menezes-Souza et al., 2011), high levels of IL-12 and
impaired TGF- production would indicate the establish-
ment of immunoprotective mechanisms induced by LBSap
vaccination.
IFN- is considered an important pro-inﬂammatory
cytokine for establishing protective immunity against the
Leishmania parasite, inducing NO synthesis, and activat-
ing microbicidal function in macrophages (Trinchieri et al.,
1993; Reiner and Locksley, 1995). Thus, NO is considered
one of the most important molecules responsible for killing
intracellular parasites such as those of the Leishmania genus
(Heinzel et al., 1989; Bogdan, 2001; Sisto et al., 2001;
Gradoni and Ascenzi, 2004). In this context, we  found that
the LBSap group had increased levels of IFN- after the
vaccine protocol (T3), presenting sustained improvement
at the early (T90) and late (T885) time points after L. cha-
gasi experimental challenge in the presence of the SLcA
stimulus, compared to T0. Interestingly, after the vacci-
nation protocol (T3), the LBSap group showed increased
levels in IFN- in VSA or SLcA- stimulated cultures com-
pared to other groups. Moreover, in both early (T90) and
late (T885) period post challenge, the LBSap group remained
producing increased levels of Leishmania-speciﬁc IFN-, as
ry Paras
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compared to the respective stimulated cultures (VSA or
SLcA) from the other groups. Furthermore, the increased
IFN- levels at T885 was concomitant with higher NO
amounts in cultures stimulated with SLcA and VSA. Since
IFN- is associated with a resistance proﬁle to Leishmania
infection in different experimental models (Squires et al.,
1989; Andrade et al., 1999; Murray et al., 1992; Carrillo
et al., 2007; Fernandes et al., 2008), our data revealed an
intense Leishmania-speciﬁc induction of IFN- after immu-
nization with LBSap.
Considering the lack of a sufﬁcient amount of biological
material, we performed PCR analysis to assess the parasite
burden. However, only the LBSap and LB groups showed
one dog each with positive parasitological results, which
may  indicate that the antigen of L. braziliensis can induce
protection after experimental L. chagasi challenge. Further
investigations will focus on the efﬁcacy of the LBSap vac-
cination in protecting against an experimental challenge
with L. chagasi,  using quantitative PCR.
In conclusion, our data point to a prominent type 1
immune response is elicited by higher levels of IL-12 and
IFN- following complete vaccination and after L. chagasi
challenge. Additionally, the levels of TGF- are reduced in
the early immune response after L. chagasi challenge, while
NO production is enhanced at a late time point following
L. chagasi challenge. Furthermore, based on bone mar-
row parasitological analysis, the frequency of parasitism
is decreased in the presence of the vaccine antigen. Thus,
LBSap vaccine appears to elicit prominent, long-lasting
type 1 immunogenicity.
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